Heparin-Coated Polyacrylonitrile Membrane Versus Regional Citrate Anticoagulation: A Prospective Randomized Study of 2 Anticoagulation Strategies in Patients at Risk of Bleeding

American Journal of Kidney Diseases

Volumn 49, Issue 5, 2007, Pages 642-649

  Evenepoel, Pieter ^a   Dejagere, Tom ^a   Verhamme, Peter ^a   Claes, Kathleen ^a   Kuypers, Dirk ^a   Bammens, Bert ^a   Vanrenterghem, Yves ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Anticoagulation; citrate; hemodialysis; heparin

Indexed keywords

CALCIUM; CITRIC ACID; HEPARIN; POLYACRYLONITRILE; POLYSULFONE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ARTIFICIAL KIDNEY; BLEEDING; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSATE; DRUG COATING; FEMALE; HEMODIALYSIS; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBUS;

ACRYLIC RESINS; ADULT; AGED; ANTICOAGULANTS; CITRIC ACID; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS;

EID: 34247475274     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.02.001     Document Type: Article

References (22)

1. Ward R.A. Effects of haemodialysis on coagulation and platelets: Are we measuring membrane biocompatibility?. Nephrol Dial Transplant 10 suppl 10 (1995) S12-S17
2. Janssen M.J.F.M., and Van der Meulen J. The bleeding risk in chronic hemodialysis: Preventive strategies in high-risk patients. Neth J Med 48 (1996) 198-207
3. Sanders P.W., Taylor H., and Curtis J.J. Hemodialysis without anticoagulation. Am J Kidney Dis 5 (1985) 32-35
4. Swartz R.D. Hemorrhage during high-risk hemodialysis using controlled heparinization. Nephron 28 (1981) 65-69
5. Evenepoel P., Maes B., Vanwalleghem J., Kuypers D., Messiaen T., and Vanrenterghem Y. Regional citrate anticoagulation for hemodialysis using a conventional calcium-containing dialysate. Am J Kidney Dis 39 (2002) 315-323
6. Apsner R., Buchmayer H., Lang T., et al. Simplified citrate anticoagulation for high-flux hemodialysis. Am J Kidney Dis 38 (2001) 979-987
7. Wright M.J., Woodrow G., Umpleby S., Hull S., Brownjohn A.M., and Turney J.H. Low thrombogenicity of polyethylene glycol-grafted cellulose membranes does not influence heparin requirements in hemodialysis. Am J Kidney Dis 34 (1999) 36-42
8. Chanard J., Lavaud S., Randoux C., and Rieu P. New insights in dialysis membrane biocompatibility: Relevance of adsorption properties and heparin binding. Nephrol Dial Transplant 18 (2003) 252-257
9. Frank R.D., Muller U., Lanzmich R., Groeger C., and Floege J. Anticoagulant-free Genius haemodialysis using low molecular weight heparin-coated circuits. Nephrol Dial Transplant 21 (2006) 1013-1018
10. Renaux J.L., Thomas M., Crost T., Loughraieb N., and Vantard G. Activation of the kallikrein-kinin system in hemodialysis: Role of membrane electronegativity, blood dilution, and pH. Kidney Int 55 (1999) 1097-1103
11. Thomas M., Valette P., Mausset A.L., and Dejardin P. High molecular weight kininogen adsorption on hemodialysis membranes: Influence of pH and relationship with contact phase activation of blood plasma. Influence of pre-treatment with poly(ethyleneimine). Int J Artif Organs 23 (2000) 20-26
12. Zemanova P., Opatrny K., Vit L., and Sefrna F. Tissue factor, its inhibitor, and the thrombogenicity of two new synthetic membranes. Artif Organs 29 (2005) 651-657
13. Lavaud S., Canivet E., Wuillai A., et al. Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane. Nephrol Dial Transplant 18 (2003) 2097-2104
14. Lavaud S., Paris B., Maheut H., et al. Assessment of the heparin-binding AN69 ST hemodialysis membrane: II. Clinical studies without heparin administration. ASAIO J 51 (2005) 348-351
15. Renaux J.L., and Atti M. The AN69ST dialysis membrane. A new approach for reducing systemic heparinization. Contrib Nephrol 137 (2002) 111-119
16. Keller F., Seemann J., Preuschof L., and Offermann G. Risk factors of system clotting in heparin-free haemodialysis. Nephrol Dial Transplant 5 (1990) 802-807
17. Sperschneider H., Deppisch R., Beck W., Wolf H., and Stein G. Impact of membrane choice and blood flow pattern on coagulation and heparin requirement-Potential consequences on lipid concentrations. Nephrol Dial Transplant 12 (1997) 2638-2646
18. Osada H., Ward C.A., Duffin J., Nelems J.M., and Cooper J.D. Microbubble elimination during priming improves biocompatibility of membrane oxygenators. Am J Physiol 234 (1978) H646-H652
19. Apsner R., Buchmayer H., Gruber D., and Sunder-Plassmann G. Citrate for long-term hemodialysis: Prospective study of 1,009 consecutive high-flux treatments in 59 patients. Am J Kidney Dis 45 (2005) 557-564
20. Lee K.B., Kim B., Lee Y.H., et al. Hemodialysis using heparin bound hemophan in patients at risk of bleeding. Nephron Clin Pract 97 (2004) c5-c10
21. Hofbauer R., Moser D., Frass M., et al. Effect of anticoagulation on blood membrane interactions during hemodialysis. Kidney Int 56 (1999) 1578-1583
22. Bohler J., Schollmeyer P., Dressel B., Dobos G., and Horl W.H. Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: Dissociation of complement activation and neutropenia from neutrophil degranulation. J Am Soc Nephrol 7 (1996) 234-241